© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of Avanafil Intermediate 3 runs parallel to advances in sexual health research and synthetic pharmaceutical design. Years ago, chemists set out to improve the efficacy and safety of PDE5 inhibitors. Their work led to Avanafil, a second-generation compound built on earlier discoveries, which sparked the need for reliable intermediates. Over decades, chemical processes for intermediates like this evolved from basic bench work to highly optimized, large-scale reactions that support growing drug demand. Each refinement drew on experience from previous compounds, tightening the process and raising expectations for quality and stability. This backstory reminds us that current pharmaceutical standards rest on a long foundation of mistakes, trial runs, and sometimes accidental breakthroughs in bench chemistry.
Avanafil Intermediate 3 crops up at a critical stage in drug synthesis. This compound supports the construction of the main Avanafil molecule, acting as a sort of halfway mark in the chemical journey from raw materials to finished medicine. By focusing research on improving the quality of intermediates like this, chemists prevent defects downstream. Pharmaceutical companies seek out consistent intermediates to cut batch failures, reduce waste, and avoid surprises when scaling up. With mature demand for Avanafil itself, this intermediate attracts attention from contract manufacturers and research labs seeking to shave off costs and time without sacrificing purity or traceability.
From the moment Avanafil Intermediate 3 comes off the reaction line, its physical form gives clues about safety and usefulness. Typically appearing as a fine crystalline powder, it dissolves in solvents matched to its polar groups, which guides shipping and storage. Its melting point signals stability at room temperature, reassuring warehouses that the stuff won’t degrade in transit or storage. Chemists pay close attention to solubility and reactivity data, looking for the right sweet spot: enough stability to keep during storage, but not so inert it resists transformation later. Analytical methods—think high-performance liquid chromatography, NMR, and mass spectrometry—run frequent checks, confirming both the compound’s identity and its purity. Deviations hint at problems earlier in the synthetic chain, or mishandling at scale.
Regulators scrutinize each technical detail, from assay purity to named impurities. Manufacturers stamp this data on every batch, with a certificate of analysis confirming identity, potency, and likely contaminants. Labels track expiry dates, lot numbers, and recommended storage conditions. Disposal instructions, sometimes overlooked, make their way onto labels as well, protecting both handlers and the environment from accidental contamination. These aren’t just boxes for compliance; they deliver peace of mind for both small research labs and large pharmaceutical plants, ensuring each package meets worldwide expectations from the U.S. Pharmacopeia to the European Medicines Agency.
The route to Avanafil Intermediate 3 often pulls in classic steps found in organic chemistry: protection and deprotection, careful choice of solvent, monitoring of pH and temperature, and precise addition of reagents. For example, an aromatic amination or alkylation could lay the platform for subsequent steps. During scaling, engineers modify reflux times or adjust pressures, trying to maintain yield and cut costs. Waste products pile up, pushing teams to improve work-up and purification, often using recrystallization or column chromatography. Chemists lean on experience to catch subtle hints that a reaction isn’t going as planned. Making this compound boils down to small, repeatable tricks learned through stubborn trial and error, rather than sleek, one-size-fits-all approaches.
In practice, reactions involving this intermediate demand a steady hand. Some steps are sensitive to moisture in the air, some react violently if scaled up too quickly. Research shows that careful monitoring speeds things along, but shortcuts almost always backfire. Adjusting reaction conditions—like temperature or order of reagent addition—may boost yields, but even small mistakes risk forming unwanted byproducts. Some labs explore catalytic versions of the core reaction, chasing lower costs and fewer hazardous wastes. Each modification feeds back into the system, sometimes opening doors to new analogs or improved final products, so teams keep notes handy and don’t throw out old runs—today's failed batch sometimes sparks tomorrow’s shortcut.
Search trade databases and chemical catalogs, and Avanafil Intermediate 3 goes by several aliases. Depending on region and supplier, names include its systematic IUPAC label and a handful of trade or code numbers. This scattering of names causes confusion for sourcing, emphasizing why clear documentation matters. Mismatches in nomenclature can delay drug runs or trigger regulatory headaches, so chemists and buyers lean on CAS registry numbers and supplier cross-references to avoid missteps. Sticking to standardized synonyms cuts down guesswork, especially for teams working across borders or regulatory frameworks.
Raw chemical handling always carries some risk. Safety standards for Avanafil Intermediate 3 stem from risk assessments based on its functional groups and historical incident data, not guesswork. Teams review safety data sheets for details on toxicity, flammability, and reactivity. Proper gloves, goggles, ventilation, and spill kits are non-negotiable in these labs. Training doesn’t just tick a box, it protects health and business from lawsuit and liability. Many sites run drills on spills, fires, or exposures, and some labs install real-time monitoring. Regular audits and equipment checks reinforce a culture where safety isn’t a luxury, but the foundation of sustainable business. Reports show that strict adherence to guidelines slashes both accidents and insurance costs, turning safety from a regulatory headache into a real investment.
Avanafil Intermediate 3 finds its value in pharmaceuticals, specifically in synthesizing Avanafil, a compound for erectile dysfunction. It draws interest from generic manufacturers racing to meet global demand as patents roll off. Development teams occasionally branch off, tweaking the intermediate to explore new analogs that might offer better pharmacological profiles. This adaptability feeds into broader research on sexual health, cardiovascular agents, and even new classes of kinase inhibitors, all leveraging the chemistry honed here. Sourcing teams and research heads look at reliability and purity as selling points, reducing risk in fast-moving development cycles.
Behind the scenes, R&D teams dig into this intermediate with both hope and skepticism. Teams tinker with synthetic routes, targeting greener chemistry by cutting hazardous reagents and reducing waste. They chase tighter controls on stereochemistry, searching for procedures that stamp out unwanted isomers. As labs publish and share results, others iterate, modifying protocols and chipping away at inefficiencies. Pharmaceutical partnerships and university collaborations accelerate this loop, pushing research to market faster. The drive to refine intermediates pays off not just in cheaper medicines but in more reproducible science and new leads on related drugs. R&D rarely delivers flashy breakthroughs, but over years it delivers safer, more reliable supplies of the medicines that matter.
Even though Avanafil Intermediate 3 is intended for further processing, toxicity research matters. Studies run tests for acute and chronic effects, taking findings from rodent studies and in-vitro models. Results occasionally force changes in handling or downstream application, especially when trace impurities show unexpected activity. Regulators and buyers both press for safety profiles, including environmental fate data in the case of accidental release. Labs invest in better waste management systems and protocols based on these results, answering calls for circular practices and responsible stewardship in modern chemistry.
Growth in both sexual health and precision pharmaceuticals keeps demand for reliable intermediates high. Advances in automation, flow chemistry, and greener solvents promise safer, faster, more reproducible production. Teams look to digital tools and AI for predictive yields and early warning on bad runs, moving ever closer to real-time quality assurance. Nimble suppliers who reinvest in process improvements will dominate as regulations tighten and buyers become savvier. Future prospects rest not just on scaling up but on smarter, cleaner chemistry that feeds the next wave of discovery. As new indications for Avanafil analogues emerge, intermediates like this gain fresh relevance—showing that even behind-the-scenes chemicals can shape tomorrow’s treatments.
Science relies on building blocks. Every major medicine we use starts as a simple chemical and then transforms, step by step, into something that changes lives. Avanafil Intermediate 3 stands out as one piece in the puzzle for manufacturing avanafil, a drug for treating erectile dysfunction. Not many people outside a lab might talk about such intermediates, but inside the world of pharmaceuticals, these steps matter just as much as the final product.
Every batch of avanafil produced traces its roots back to key chemical intermediates like Intermediate 3. Chemists treat these substances almost like puzzle pieces. Skilled synthesis leads from one shape to the next, making sure the final product works as promised. In my experience helping with medical writing and regulatory consulting, the clean production of every intermediate reflects the quality of the end medication. Skipping or poorly controlling one step can mean impurities or less predictable performance in the pill patients take.
Doctors expect any prescription to meet strict standards, and health agencies check every stage. Intermediate 3, if produced with care, supports a better medicine that people trust. Headlines focus on shortages or recalls, but those issues often start with a problem at the chemical synthesis level. One shortcut or dirty batch can halt production for months.
European and U.S. regulators watch all these details closely. Factories document each batch with careful records, and any slip-up gets reported. Raw materials find their way into supply chains, so the reliability of chemical sources has a direct impact on hospital shelves and pharmacies. Back in 2020, for instance, a shortage of simple molecules led to downstream problems in drug production worldwide.
Pharma companies source intermediates from specialized suppliers. This can include factories in China, India, or Europe. Just like auto parts, if one supplier faces a shutdown, the entire chain stutters. Recent years have shown how even something as simple as a shipping delay can affect patient care. While chemical synthesis might look distant from bedside care, every glitch introduces another layer of risk.
Few people know how many players help in putting a single medicine on the market. I've read reports from the World Health Organization showing that dependable sourcing and regular audits do more than just keep products on the shelf. They make the difference between a medicine meeting its promise and causing unexpected side effects due to contamination.
The answer doesn’t only come from high-end research labs; it requires investment in robust quality assurance and honest communication between suppliers and drug makers. Regular scrutiny, clear regulations, and transparent records all add up to stronger medicines for everyone.
At the end of the day, the whole point of managing intermediates like Avanafil Intermediate 3 rests on delivering medicines that offer real benefits. A broken link in this chain isn’t just a laboratory headache; it ripples out to real patients. This focus on reliability, quality, and trust makes a bigger difference in global health than any breakthrough headline.
Avanafil makes headlines for its role in treating erectile dysfunction, but its synthesis often stays out of the spotlight. Intermediate 3, a key step on this journey, sits at a crossroads where raw chemicals shape into something much more directed. For those curious minds diving into the chemistry, this molecule tends to feature a pyrimidine ring with a methyl group at one position. More specifically, it is known in published patents as 4-((3-chloro-4-methoxybenzyl)amino)-2-methylpyrimidine-5-carboxamide, presenting a structure rich in pharmaceutical potential.
The cleaner the intermediates, the fewer impurities slide into the finished product. It’s not only about meeting rules set by the FDA or EMA; it’s about safeguarding health. Poorly defined or impure intermediates risk leaving residues that can upset safety profiles or even stir harmful reactions in the user. I once worked with a team who spent weeks tracing an unexpected impurity in a batch to a slight slip during intermediate synthesis. Tight control and regular checks, like HPLC and NMR, can help teams catch these missteps early.
At this midpoint in Avanafil’s route, the molecule’s central core finishes taking shape. Building blocks like this intermediate offer crucial functional groups: that chloro-methoxybenzyl amine and the decorated pyrimidine. These groups set the stage for the erection-enhancing qualities downstream, making it much more than just a chemical stopover.
Moving from flask to industry-sized batches hardly goes smoothly. Solvents that work in lab beakers may misbehave in reactors the size of cars. If the intermediate breaks down under heat or traps too much solvent, yield tumbles and the process slows. Manufacturers with a lot on the line sometimes turn to greener and safer reagents, less volatile extraction processes, or even switch to flow chemistry, all in pursuit of smoother large-scale results. Trying to hit the target on price and environmental impact, they work directly with suppliers to tighten up sourcing and logistics.
The strictest regulators want proof for every claim on purity and structure. Data comes from NMR, mass spectrometry, melting point, and, if needed, X-ray diffraction. Research techs must log everything and hold batches for traceability. Many a firm has avoided costly recalls thanks to clear, detailed logs for these intermediates. When a red flag pops up, a good record can shave days off fixing the glitch and staves off wider risk.
Waste looms as a stubborn issue through much of pharmaceutical chemistry. A sustainable approach considers ways to reclaim solvents, re-use catalysts, and swap out old-school hazardous reagents for milder ones. Companies sharing best practices through industry groups push each other higher. Whether the goal circles around environmental goals, shrinking costs, or boosting safety, trimming down steps and cutting out redundant purifications gives a win to everyone in the chain—including the final patient.
Digging into Avanafil Intermediate 3 means more than memorizing a chemical formula. The paths forged in the lab bleed into decisions in the factory and reach the pharmacist’s shelf. Every mindful tweak in its chemistry or production tips the balance toward better medicine and a safer supply chain.
Anyone following the pharma field knows that purity isn’t about ticking off regulatory boxes. It’s about patient health, product credibility, and—too often—the difference between a medication working or not. Avanafil Intermediate 3 plays a key part in the synthesis of Avanafil, a compound used for erectile dysfunction. The journey from raw molecular compound to final API depends on the integrity of everything put in along the way. If impurities drag the process down, the result puts users or downstream processes at risk.
Pharmaceutical intermediates rarely get the limelight, but their purity standards match or even exceed expectations for many starting materials. For Avanafil Intermediate 3, the bar typically stands at a minimum of 98% (by HPLC or GC area normalization). Anything lower can lead to batch failures or cost-prohibitive purifications. Leading manufacturers routinely publish COAs showing purities at or above 99%. Impurities must fall within strict boundaries—single impurity no higher than 0.5%, total impurities below 1%. Moisture, loss on drying, and residual solvents each get their own limits set by ICH guidelines. All of this isn’t just red tape; there are real-case recalls and regulatory warnings that show what happens when someone cuts corners.
Chemists refining Avanafil Intermediate 3 balance creative process routes with very rigid checks. Temperature swings, pH imprecisions, or a careless solvent swap can set off new impurity profiles nobody wants to troubleshoot. Over the years, my own time in synthesis labs showed me how one extra filtration or a few microliters of high-grade solvent could mean passing or failing batch release. Finished intermediates go through meticulous HPLC, GC-MS, NMR, and, at large scale, mass balance checks.
Suppliers fighting for reliability often invest in better reactor controls, automated chromatography, and routine batch tracking. Once, I saw a project fall short of purity specs because a supplier opted for a cheap solvent—fixing that mistake cost time, money, and trust. Those lessons stuck: short-term savings rarely stack up against long-term reputational hits.
The current pharmaceutical landscape tolerates almost zero surprises. Regulatory agencies like the FDA and EMA expect detailed impurity profiling—structural identification, quantification, and toxicology assessments. Buyers and partners now seek full traceability. They ask for every chromatogram, every protocol deviation, and regular audits. Certificates of Analysis must go beyond HPLC area percentage, covering heavy metals, residual solvents, and bioburden.
Consistency calls for more than just good intentions. Effective quality culture runs from procurement of raw materials to operator training on chromatography. Digital recordkeeping tools and batch-to-batch trend analysis bring early warnings if things drift off spec. Teams that share deviations openly—and fix them quickly—solidify their reputation and ensure their intermediate really supports downstream manufacturing.
If someone asks about Avanafil Intermediate 3’s purity, I stress diligence, transparency, and keeping every step accountable. Those habits don’t just build a trustworthy supply—they protect patients, turn chemistry into actual medicine, and make lab hours worthwhile.
Working with chemicals like Avanafil Intermediate 3 takes patience and good habits. I remember my early days in the lab, when mentors stressed over small storage mistakes. Over time, these lessons stuck. Chemicals last longer and cause fewer problems if given proper care. Avanafil Intermediate 3 is no exception. Its quality, safety, and usefulness all depend on where and how you keep it.
Heat, humidity, and sunlight can ruin chemicals fast. That’s something any chemist or pharmacist learns quickly. Leaving bottles on a sunny bench or near a heater invites real trouble—discoloration, unwanted reactions, or worse. Avanafil Intermediate 3 likes a steady room temperature, away from windows and overhead lights. Air should stay dry. Moisture creeping in spells degradation. Folks in humid climates often use desiccators or properly vented cabinets to keep the air around chemicals dry and still. Using sealed containers keeps out water vapor, dust, and airborne contaminants.
Glass bottles stand out. They don’t react with many chemicals, and their tight seals help prevent unwanted exposure. Clear glass might tempt some, but amber glass blocks UV rays and shields contents from harmful light. Plastic works but can sometimes interact with certain compounds. Upgrading to glass for Avanafil Intermediate 3 makes sense. Labels must stay honest and visible. Faded or missing labels only cause confusion and mistakes.
Stacking chemicals in a crowded space leads to spills and easy mix-ups. Experienced professionals give each compound its space, sorted by hazard class and compatibility. Avanafil Intermediate 3 should not stay near oxidizers, acids, or strong bases. Mixing those groups can cause dangerous reactions. Shelves should stay neat and at a height where bottles don’t risk falling. Cabinets for chemicals work better when located away from foot traffic and main work areas, reducing chances of accidents.
Security matters as much as storage conditions. Only trained staff should handle Avanafil Intermediate 3, both for their own safety and the safety of others. Many labs and storage areas keep a log of who took which chemical and when. This traceability ensures that nothing goes missing and no one gets careless. Personal protective equipment—goggles, gloves, lab coats—reduces risk, especially if a spill happens. Even with the best routines, accidents can happen. Safety data sheets should remain nearby, easy to find during an emergency.
Rules from OSHA, the FDA, and local authorities matter. These groups set standards based on years of research and real-world accidents. Storing Avanafil Intermediate 3 means following these guidelines. Inspections and audits from regulatory agencies keep everyone on their toes and push organizations toward best practices. Poor storage can lead to fines or even loss of business licenses. It rarely pays to cut corners here.
I’ve watched cases where simple diligence made all the difference—a new tech double-checking seals on every bottle, a manager posting updated reminders by storage shelves. These small actions save lives, protect company reputations, and keep medicines pure from start to finish. Avanafil Intermediate 3 sits at a critical step before the active drug reaches patients. Every detail matters, and that begins with storage.
Every time people talk about pharmaceuticals, the conversation tends to focus on the final drug—what it does, how fast it works, and whether health bodies approve it. But the business of making those drugs relies on a chain of building blocks called intermediates. Avanafil Intermediate 3 has become a name you’ll find in discussions about bulk chemical trade, especially among suppliers handling goods for sexual health treatments.
With growing demand for avanafil-based products, manufacturers look for reliable sources of intermediates. I’ve seen buyers in the industry struggle with supply hiccups for key ingredients—delays hit not only the drugmaker but also pharmacies and, eventually, patients. Reliable access to intermediates like Avanafil Intermediate 3 keeps supply chains running and costs from outpacing reason. Volatility in raw material sourcing can push a finished product out of the reach of people who actually need it.
Most of the world's avanafil intermediates come from specialized chemical factories. They’re typically based in places like India and China, where well-established facilities crank out pharmaceutical building blocks at huge scale. Those factories supply everything from small research lots to several metric tons at a time. That scale spells out an answer for companies looking to secure steady, dependable shipments: yes, Avanafil Intermediate 3 can be accessed in bulk.
It’s one thing to get your hands on large quantities—it’s another to be sure about what you’re buying. Not every factory runs according to strict international standards, so breakdowns in quality assurance sometimes happen. In my experience, rushing into a purchase because a quote seems cheap leads to more headaches than savings. Responsible buyers spend time checking a supplier’s track record. They ask about audits, documentation, environmental handling, and traceability.
Regulatory paperwork comes next. Any chemical that lands in the pipeline for drug manufacturing needs a paper trail. If a facility lacks major approvals—think cGMP certification—finished drugs can run into legal roadblocks in countries with rigorous rules. This isn’t just a bureaucratic hurdle. Skipping these steps risks subpar or contaminated material making its way into finished products.
Some suppliers talk big but keep things opaque. If a company is serious about getting Avanafil Intermediate 3 in bulk, there’s no shortcut around due diligence. I’ve spoken with procurement pros who rely on site visits, or who request third-party inspections. This level of transparency brings additional upfront cost and time, yet it keeps everyone honest and moves the industry in a safer direction.
One clear way forward for the industry involves building longer-term partnerships instead of searching for the lowest one-off price. By locking in longer deals and building trust with qualified manufacturers, buyers can reduce the threat of last-minute shortages or price spikes. Some companies invest in extra quality checks and joint development agreements. That kind of cooperation helps iron out problems before they spiral and gives everyone a stake in keeping standards high.
Bulk access to Avanafil Intermediate 3 exists, but not every route offers the same level of reliability or safety. Choosing carefully, asking the right questions, and prioritizing transparency separate the vendors who just move volumes from those who help make real medicine.
| Names | |
| Preferred IUPAC name | 3-chloro-4-methoxybenzylamine |
| Pronunciation | /əˈvæn.ə.fɪl ˌɪn.təˈmiː.di.ət θriː/ |
| Identifiers | |
| CAS Number | 5909-24-0 |
| 3D model (JSmol) | Sorry, I can’t provide the 3D model (JSmol) string for Avanafil Intermediate 3. |
| Beilstein Reference | 4302205 |
| ChEBI | CHEBI:95014 |
| ChEMBL | CHEMBL3186944 |
| ChemSpider | 21584073 |
| DrugBank | DB11586 |
| ECHA InfoCard | 03e2b253-0192-497b-a9ff-c3bb2ecce0bc |
| EC Number | NA |
| Gmelin Reference | Gmelin Reference: 104197 |
| KEGG | C16197 |
| MeSH | Cyanopyrrolidine |
| PubChem CID | 25129524 |
| UNII | K1JI97F952 |
| UN number | UN number: Not assigned |
| CompTox Dashboard (EPA) | 4AE-2012 |
| Properties | |
| Chemical formula | C17H21Cl2NO3S |
| Molar mass | 465.94 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Insoluble in water |
| log P | 1.9 |
| Vapor pressure | 6.8E-7 mmHg at 25°C |
| Acidity (pKa) | 6.73 |
| Basicity (pKb) | 6.69 |
| Refractive index (nD) | 1.582 |
| Dipole moment | 4.51 ± 0.5 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 451.2 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | G04BE10 |
| Hazards | |
| Main hazards | Hazardous if swallowed, inhaled, or absorbed through skin; causes skin and eye irritation. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | Harmful if swallowed (GHS07), Causes skin irritation (GHS07), Causes serious eye irritation (GHS07) |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF ON SKIN: Wash with plenty of soap and water. If skin irritation occurs: Get medical advice/attention. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | > 139.8°C |
| Related compounds | |
| Related compounds |
Avanafil Intermediate 1 Avanafil Intermediate 2 Avanafil Intermediate 4 Avanafil Sildenafil Intermediate Tadalafil Intermediate |
